GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Purchase Of Business

Akari Therapeutics (FRA:CLA) Purchase Of Business : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Purchase Of Business?

Akari Therapeutics's purchase of business for the three months ended in Dec. 2024 was €0.00 Mil. It means Akari Therapeutics spent €0.00 Mil on purchasing business. Akari Therapeutics's purchase of business for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Sep. 2024 ), Akari Therapeutics spent the same money on purchasing business in Dec. 2024 (€0.00 Mil).


Akari Therapeutics Purchase Of Business Historical Data

The historical data trend for Akari Therapeutics's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Purchase Of Business Chart

Akari Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Purchase Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Purchase Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Akari Therapeutics Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akari Therapeutics Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Akari Therapeutics Business Description

Traded in Other Exchanges
Address
22 Boston Wharf Road, Boston, MA, USA, 02210
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Akari Therapeutics Headlines

From GuruFocus

Carl Bass to Join Ouster as Chairman of the Board of Directors

By Business Wire Business Wire 02-17-2021